April 20, 2026, Montréal, Canada – Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to announce its participation in a strategic scientific collaboration with Sorintellis, Université de Montréal, Université Laval and IVADO.
The collaboration aims to advance a next-generation AI-powered clinical trial intelligence platform, TrialsBank™, designed to improve clinical trial execution, patient outcomes and operational performance across global development programs.
AI-Powered Clinical Trial Intelligence to Improve Execution and Reduce Risk
As clinical trials become more complex, sponsors face increasing challenges related to clinical trial delays, data fragmentation and execution risk. While large volumes of data are generated, the ability to convert that data into actionable clinical insights remains limited.
TrialsBank™ addresses this gap by creating a structured clinical trial intelligence layer that enables:
- Real-time analysis of clinical trial data and operational metrics
- Early identification of clinical trial risks and performance gaps
- Predictive insights to improve clinical study timelines and efficiency
- Standardized frameworks for risk-based clinical trial management
This approach supports a transition from reactive trial management to proactive, intelligence-driven clinical operations.
Vantage BioTrials Strengthens Clinical Trial Execution Through AI and Risk-Based Oversight
As a CRO focused on inspection-ready clinical trial execution, Vantage BioTrials contributes deep expertise in translating data-driven insights into operational performance and measurable outcomes.
“Clinical trials do not fail due to a lack of data. They fail when risks are not identified early or managed effectively,” said Vatche Bartekian, President of Vantage BioTrials. “By integrating AI-powered intelligence with disciplined clinical trial execution, this collaboration has the potential to significantly improve study timelines, quality and overall success rates.”
Vantage BioTrials will support the initiative through its capabilities in:
- Risk-based monitoring (RBM) and proactive risk mitigation
- Clinical trial project management and operational oversight
- Quality-by-Design (QbD) implementation
- Regulatory-aligned, inspection-ready clinical trial delivery
“AI can generate insights, but clinical trial success ultimately depends on execution,” added Viken Bartekian, VP Corporate Development. “Our role is to ensure that these insights translate into aligned execution across sites, regions and programs, where performance is determined.”
Academic and AI Expertise Advancing Clinical Research Innovation
The collaboration leverages advanced research capabilities from Université de Montréal, Université Laval and IVADO to support:
- Machine learning models for clinical trial optimization
- Data standardization for multi-study clinical programs
- Scalable AI frameworks for clinical research analytics
Sorintellis leads the development of the TrialsBank™ platform, focusing on AI-driven solutions for clinical research and drug development.
What This Means for Sponsors and Clinical Development Programs
For biotechnology and pharmaceutical companies, this collaboration introduces a new approach to clinical trial performance management, enabling:
- Improved clinical trial timelines and milestone predictability
- Reduced operational and regulatory risk
- Enhanced data-driven decision-making in clinical development
- Greater consistency in multi-site and global clinical trials
This model aligns with evolving regulatory expectations, including ICH E6(R3), which emphasize risk-based quality management and continuous oversight throughout the clinical trial lifecycle.
About Vantage BioTrials
Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology and medical device industries. Known for its personalized service model, strategic value and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector.
Forward-Looking Statements
This press release contains forward-looking statements regarding the expected impact of AI-driven clinical trial intelligence and the TrialsBank™ platform. Actual results may vary based on technological, regulatory and operational factors.